LISATA THERAPEUTICS, INC. Income (Loss) from Continuing Operations, Per Diluted Share
LISATA THERAPEUTICS, INC. (LSTA) reported Income (Loss) from Continuing Operations, Per Diluted Share of -$1.78 per share for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2018-03-22
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2017 was -$1.78.
- LISATA THERAPEUTICS, INC. income (loss) from continuing operations, per diluted share for fiscal 2016 was -$4.74.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|
| 2017-12-31 | -$1.78 10-K · filed 2018-03-22 |
| 2016-12-31 | -$4.74 10-K · filed 2018-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| BIOVIE INC. (BIVI) | United States | $0.012B |